Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher P Cannon

Showing results (581-590 of 706) with videos related to

Pageof 71
Sort By:
Circulation|March 3, 2010
Effect of rosiglitazone on progression of coronary atherosclerosis in patients with type 2 diabetes mellitus and coronary artery disease: the assessment on the prevention of progression by rosiglitazone on atherosclerosis in diabetes patients with cardiovascular history trialHertzel C Gerstein, Robert E Ratner, Christopher P Cannon, et al.
Circulation. Cardiovascular Quality and Outcomes|May 13, 2020
Copayment Reduction Voucher Utilization and Associations With Medication Persistence and Clinical Outcomes: Findings From the ARTEMIS TrialAlexander C Fanaroff, Eric D Peterson, Lisa A Kaltenbach, et al.
Circulation|May 30, 2020
Comparative Efficacy and Safety of Oral P2Y<sub>12</sub> Inhibitors in Acute Coronary Syndrome: Network Meta-Analysis of 52 816 Patients From 12 Randomized TrialsEliano P Navarese, Safi U Khan, Michalina Kołodziejczak, et al.
Circulation|February 11, 2004
Differential expression of cardiac biomarkers by gender in patients with unstable angina/non-ST-elevation myocardial infarction: a TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis In Myocardial Infarction 18) substudyStephen D Wiviott, Christopher P Cannon, David A Morrow, et al.
Archives of Internal Medicine|April 12, 2006
Clopidogrel to treat patients with non-ST-segment elevation acute coronary syndromes after hospital dischargePierluigi Tricoci, Matthew T Roe, Jyotsna Mulgund, et al.
Circulation|December 10, 2008
Sex differences in medical care and early death after acute myocardial infarctionHani Jneid, Gregg C Fonarow, Christopher P Cannon, et al.
European Heart Journal|June 19, 2010
Patients with acute coronary syndromes and elevated levels of natriuretic peptides: the results of the AVANT GARDE-TIMI 43 TrialBenjamin M Scirica, David A Morrow, Christoph Bode, et al.
Journal of the American College of Cardiology|January 30, 2016
Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome: The IMPROVE-IT TrialSabina A Murphy, Christopher P Cannon, Michael A Blazing, et al.
Journal of the American College of Cardiology|October 29, 2013
Lipoprotein(a) for risk assessment in patients with established coronary artery diseaseMichelle L O'Donoghue, David A Morrow, Sotirios Tsimikas, et al.
Clinical Chemistry|November 5, 2016
Growth Differentiation Factor 15 Predicts All-Cause Morbidity and Mortality in Stable Coronary Heart DiseaseEmil Hagström, Claes Held, Ralph A H Stewart, et al.
Pageof 71

Showing results (581-590 of 706) with videos related to

Sort By:
Pageof 71
Circulation|March 3, 2010
Effect of rosiglitazone on progression of coronary atherosclerosis in patients with type 2 diabetes mellitus and coronary artery disease: the assessment on the prevention of progression by rosiglitazone on atherosclerosis in diabetes patients with cardiovascular history trialHertzel C Gerstein, Robert E Ratner, Christopher P Cannon, et al.
Circulation. Cardiovascular Quality and Outcomes|May 13, 2020
Copayment Reduction Voucher Utilization and Associations With Medication Persistence and Clinical Outcomes: Findings From the ARTEMIS TrialAlexander C Fanaroff, Eric D Peterson, Lisa A Kaltenbach, et al.
Circulation|May 30, 2020
Comparative Efficacy and Safety of Oral P2Y<sub>12</sub> Inhibitors in Acute Coronary Syndrome: Network Meta-Analysis of 52 816 Patients From 12 Randomized TrialsEliano P Navarese, Safi U Khan, Michalina Kołodziejczak, et al.
Circulation|February 11, 2004
Differential expression of cardiac biomarkers by gender in patients with unstable angina/non-ST-elevation myocardial infarction: a TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis In Myocardial Infarction 18) substudyStephen D Wiviott, Christopher P Cannon, David A Morrow, et al.
Archives of Internal Medicine|April 12, 2006
Clopidogrel to treat patients with non-ST-segment elevation acute coronary syndromes after hospital dischargePierluigi Tricoci, Matthew T Roe, Jyotsna Mulgund, et al.
Circulation|December 10, 2008
Sex differences in medical care and early death after acute myocardial infarctionHani Jneid, Gregg C Fonarow, Christopher P Cannon, et al.
European Heart Journal|June 19, 2010
Patients with acute coronary syndromes and elevated levels of natriuretic peptides: the results of the AVANT GARDE-TIMI 43 TrialBenjamin M Scirica, David A Morrow, Christoph Bode, et al.
Journal of the American College of Cardiology|January 30, 2016
Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome: The IMPROVE-IT TrialSabina A Murphy, Christopher P Cannon, Michael A Blazing, et al.
Journal of the American College of Cardiology|October 29, 2013
Lipoprotein(a) for risk assessment in patients with established coronary artery diseaseMichelle L O'Donoghue, David A Morrow, Sotirios Tsimikas, et al.
Clinical Chemistry|November 5, 2016
Growth Differentiation Factor 15 Predicts All-Cause Morbidity and Mortality in Stable Coronary Heart DiseaseEmil Hagström, Claes Held, Ralph A H Stewart, et al.
Pageof 71